You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

87 Results
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Nov 2018
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    brigatinib - For the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brigatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Mar 2018
Guidelines and Advice
Status: In-Review
ID: 7-14
Version: 3
Dec 2018
Guidelines and Advice
Status: Current
ID: N/A
Version: Final
May 2018
Guidelines and Advice
Status: In-Review
ID: ES 15-16
Oct 2018
Regimen
Cancer Type:
Hematologic
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
acalabrutinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024
Drug
Other Name(s): Calquence®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2024
Statistical Reports
Apr 2018
Statistical Reports
Apr 2018
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
acalabrutinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024

Pages